Ascendis Pharma ADR

At the Morgan Stanley conference Ascendis Pharma said it expects more than €500m in operating cash flow in 2026, will start a $400m share buyback program and does not plan to raise equity. The company set a long-term product revenue target of €5bn by 2030, anchors its business on three approved products—SKYTROFA, YORVIPATH (projected blockbuster status in 2026) and YUVIWEL—and sees strong early market dynamics. Ascendis has reclaimed the metabolic and cardiovascular franchise from Novo Nordisk and plans a cardiometabolic pipeline with studies starting in 2027. Several late-stage clinical programs are underway; results from two to three Phase III studies are expected in 2027. » More on de.investing.com

The board of directors of Ascendis Pharma has approved a share buyback program of up to $400 million. Purchases may be made over time in the open market, through privately negotiated transactions, block trades, accelerated buybacks and 10b5-1 plans. The size and timing will depend on market conditions and the share price; the program does not obligate the company to repurchase any specific number of shares and may be amended or terminated at any time. » More on de.investing.com

Ascendis is presenting 104-week data from the ApproaCH study of once-weekly TransCon CNP (YUVIWEL) in children with achondroplasia at the annual meeting of the International Skeletal Dysplasia Society, including data from the open-label extension. YUVIWEL received FDA approval in February 2026 for pediatric patients aged two years and older; an EMA decision is expected in Q4 2026. Ascendis is also showing a poster on injection site reactions when an indirect treatment comparison is not possible. » More on de.investing.com